Differences in vasculature between pilocytic and anaplastic astrocytomas of childhood

Benjamin Gesundheit1, Giannoula Klement, Christof Senger

  • 1Department of Paediatrics, New Agent and Innovative Therapy Program, Toronto, Ontario, Canada.

Insights

Anaplastic astrocytoma (AA) has immature vasculature, unlike pilocytic astrocytoma (PA). This suggests AA may respond better to anti-angiogenic therapies targeting its unique vascular profile.

Area of Science:

  • Neuro-oncology
  • Vascular biology
  • Cancer research

Background:

  • Childhood pilocytic astrocytoma (PA) and anaplastic astrocytoma (AA) exhibit distinct clinical behaviors and prognoses.
  • Aggressive anaplastic astrocytoma (AA) is paradoxically found with lower microvessel density than pilocytic astrocytoma (PA).

Purpose of the Study:

  • To investigate the microvasculature differences between pilocytic astrocytoma (PA) and anaplastic astrocytoma (AA).
  • To differentiate mature versus immature vessels in PA and AA using specific markers.

Main Methods:

  • Utilized antibodies for Factor VIII (FVIII) to identify endothelial cells (ECs) and alpha-smooth muscle actin (alpha-SMA) to assess vessel maturity.
  • Examined the expression patterns of vascular endothelial growth factor (VEGF) and its receptor, flt-1/VEGFR-1.

Main Results:

  • Pilocytic astrocytoma (PA) predominantly features large, mature, alpha-SMA-positive vessels (54.5% maturation index).
  • Anaplastic astrocytoma (AA) is characterized by small, immature, alpha-SMA-negative vessels (6.1% maturation index).
  • VEGF was mainly in PA astrocytes, while flt-1/VEGFR-1 was detected in AA tumor cells.

Conclusions:

  • The immature vasculature of anaplastic astrocytoma (AA) suggests increased susceptibility to anti-angiogenic therapies.
  • VEGF and flt-1/VEGFR-1 expression in AA tumor cells may indicate an autocrine growth function, supporting anti-angiogenesis as a therapeutic strategy for AA.
Abstract

Related Concept Videos